Clinical phenotypes related to smoking cessation

被引:1
|
作者
Minas, Markos [1 ]
Apostolidou, Eleni [1 ,2 ]
Goudouva, Irene [1 ]
Makris, Elias [1 ]
Gourgoulianis, Konstantinos I. [1 ]
Hatzoglou, Crissi [1 ,2 ]
机构
[1] Univ Thessaly Med Sch, Dept Resp Med, Larisa 41110, Biopolis, Greece
[2] Univ Thessaly Med Sch, Dept Physiol, Larisa 41110, Biopolis, Greece
关键词
Cluster analysis; Phenotypes; Smoking cessation; LUNG-FUNCTION; VARENICLINE; SMOKERS; PREDICTORS; BUPROPION; HEALTH; ASTHMA; NEUROBIOLOGY; COMPONENT; RELAPSE;
D O I
10.1016/j.jsat.2012.08.002
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Introduction: The aim of the current study is the identification of clinical phenotypes of patients visiting a specialized smoking cessation center and the determination of smoking cessation rate for each phenotype, 1 year after the initial evaluation. Methods: Seven hundred eighty-three smokers who visited the outpatient clinic were included in the study. Demographic data, smoking habits, tobacco dependence and comorbidities were recorded. Smoking cessation rates and carbon monoxide levels were determined 1 year after the initial evaluation. Results: The overall smoking cessation rate 1 year after the initial evaluation was 32.3%. Four distinct phenotypes were identified. The first one included mainly young women with low tobacco dependence and allergic profile. The second and the third ones included mainly men with high tobacco dependence, without comorbidities, treated with varenicline and bupropione SR, respectively. The fourth one included mainly older men with high tobacco dependence and smoking related comorbidities. Smoking cessation rates for each phenotype were 33.8, 39.4, 23.3, and 24.6%, respectively. Conclusion: Patients visiting a specialized smoking cessation center can be categorized in different phenotypes. Phenotyping may lead to a more personalized approach concerning smoking cessation. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:288 / 294
页数:7
相关论文
共 50 条
  • [21] Clinical experience of varenicline for smoking cessation
    Jung, Jae Woo
    Jeon, Eun Ju
    Kim, Jae Gyu
    Yang, Suh-Yoon
    Choi, Jae Chol
    Shin, Jong Wook
    Park, In Won
    Choi, Byoung Whui
    Kim, Don-Kyu
    Kim, Jae Yeol
    [J]. CLINICAL RESPIRATORY JOURNAL, 2010, 4 (04): : 215 - 221
  • [22] Smoking cessation and anxiety in a clinical sample
    Becoña, E
    Vázquez, FL
    Míguez, MD
    [J]. PERSONALITY AND INDIVIDUAL DIFFERENCES, 2002, 32 (03) : 489 - 494
  • [23] Abuse and smoking cessation in clinical practice
    Smith, Patricia M.
    Spadoni, Michelle M.
    Proper, Veronica M.
    [J]. JOURNAL OF CLINICAL NURSING, 2014, 23 (3-4) : 361 - 366
  • [24] Smoking cessation interventions in clinical practice
    Rabenstein A.
    Aydin D.
    Lochbühler K.
    [J]. MMW - Fortschritte der Medizin, 2021, 163 (15) : 32 - 34
  • [25] Smoking cessation interventions in clinical practice
    Cornuz, J.
    [J]. EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2007, 34 (04) : 397 - 404
  • [26] WORK-RELATED CONSEQUENCES OF SMOKING CESSATION
    MANNING, MR
    OSLAND, JS
    OSLAND, A
    [J]. ACADEMY OF MANAGEMENT JOURNAL, 1989, 32 (03): : 606 - 621
  • [27] Behavioral activation for smoking cessation and the prevention of smoking cessation-related weight gain: A randomized trial
    Audrain-McGovern, Janet
    Wileyto, E. Paul
    Ashare, Rebecca
    Albelda, Benjamin
    Manikandan, Divya
    Perkins, Kenneth A.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2023, 244
  • [28] Bupropion: pharmacological and clinical profile in smoking cessation
    Haustein, KO
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2003, 41 (02) : 56 - 66
  • [29] Clinical experience with lobeline as a smoking cessation agent
    Schneider, FH
    Olsson, TA
    [J]. MEDICINAL CHEMISTRY RESEARCH, 1996, 6 (7-8) : 562 - 570
  • [30] Clinical Efficacy of Bupropion in the Management of Smoking Cessation
    Douglas Jorenby
    [J]. Drugs, 2002, 62 : 25 - 35